AlphAIAlphAI — Financial news for AI agents
tradingview.com$MAIA

MAIA Biotechnology 3Q 2026: EPS ($0.12) — 10-Q Summary

MAIA Biotechnology reported a narrower net loss of $7.18M in 3Q 2026, with EPS at ($0.12), compared to ($0.27) a year ago. The company had no revenue but reduced R&D expenses by 16%. THIO-104 trial enrollment reached 65 patients, and THIO-101 U.S. trial expansion began. Spain and Portugal approved patient screening for THIO-104.

Original reporting
tradingview.com
Published Nov 9, 2026, 10:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
MAIA Biotechnology 3Q 2026: EPS ($0.12) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$MAIANeutralMed
01

Why it matters

The filing provides the first public disclosure of the quarter's financial results, highlighting a narrowed loss and progress in clinical trials.

02

Market read

Primary earnings disclosure for a micro‑cap biotech; relevance mainly to traders focused on biotech earnings and pipeline updates.

03

What to watch

Potential upcoming regulatory outcomes for THIO‑104 trial could materially change valuation.

Relevance 6/10Novelty 7/10Timing: post‑market release

Background

The article is an AI‑generated summary of MAIA Biotechnology's Form 10‑Q filing for Q3 2026.

Company-level read

Ticker impact

$MAIANeutralHigh confidence
Context

Q3 2026 10‑Q shows net loss narrowed to $7.18M and EPS improved to -$0.12 versus -$0.27 a year ago.

Expected impact

modest upside as the market prices in the loss improvement

Evidence & confidence

The primary disclosure of better loss metrics is new information; traders may take a small long position or hold existing positions.

Market effects

Sector

Biotech sector may see slight positive bias as a peer reports loss improvement.

Regional

Limited to U.S. biotech investors.

Global

Low; impact confined to niche biotech investors.

Counterpoint

What could challenge this read

Despite loss narrowing, the lack of revenue and ongoing R&D spend could keep the stock under pressure.

Key entities

  • company
    MAIA Biotechnology, Inc.

    U.S. listed biotech company reporting Q3 2026 results.

Read at source← All news

Related articles

$MAIAMedAI 8/10

MAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%

MAIA Biotechnology (MAIA) announced completing enrollment for Part C of its Phase 2 THIO-101 trial and 65% completion for its Phase 3 THIO-104 trial, both evaluating ateganosine in NSCLC. The company reported a 90.5% interim disease control rate for the combination therapy. MAIA aims to enroll 100 patients in THIO-104 by 2026, with an interim analysis planned for 2027. The FDA granted Fast Track designation to ateganosine in July 2025. MAIA shares are up 0.85% at $1.20.

rttnews.com
$MAIAMedAI 9/10

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

MAIA Biotechnology (NYSE American: MAIA) reported milestones in its Phase 2 and Phase 3 trials for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). Enrollment is complete for Part C of the Phase 2 trial, with 90.5% interim disease control reported. The Phase 3 trial has reached 65% of its 100-patient enrollment target. The FDA granted Fast Track designation to ateganosine in July 2025.

globenewswire.com